Every year, about 1 million people living with HIV worldwide develop tuberculosis. Although
the drug regimens used to treat tuberculosis in these patients are the same as those used in …

Tuberculosis (TB) is the leading cause of death in people living with HIV (PLHIV) globally,
causing 208,000 deaths in PLHIV in 2019. PLHIV have an 18-fold higher risk of TB, and …

Tuberculosis (TB) is a global health threat, killing approximately 1.5 million people each
year. The eradication of Mycobacterium tuberculosis, the main causative agent of TB, is …

Abstract Background The World Health Organization (WHO) End TB strategy aims to reduce
mortality due to tuberculosis (TB) to less than 5% by 2035. However, mortality due to …

Background Subclinical tuberculosis is an asymptomatic disease phase with important
relevance to persons living with HIV. We describe the prevalence, clinical characteristics …

Mycobacterium tuberculosis (Mtb) resides in a quarter of the world's population and is the
causative agent for tuberculosis (TB), the most common infectious reason of death in …

BACKGROUND: Treating multidrug-resistant TB (MDR-TB) remains challenging. However,
the determinants and timing of poor outcomes during MDR-TB treatment are still poorly …

Background Tuberculosis is the primary cause of hospital admission in people living with
HIV, and the likelihood of death in the hospital is unacceptably high. The Alere Determine …

Die Tuberkulose ist in Deutschland eine seltene, überwiegend gut behandelbare
Erkrankung. Weltweit ist sie eine der häufigsten Infektionserkrankungen mit ca. 10 Millionen …

Introduction Fostemsavir is a gp120-directed attachment inhibitor approved for heavily
treatment-experienced (HTE) adults with multidrug-resistant HIV-1. We provide detailed …